Form 4: CERo Therapeutics Director Michael Byrnes Granted Stock Options, Establishes Power of Attorney for SEC Filings

CERo Therapeutics Holdings, Inc. (CERO) Director Michael Byrnes was granted 9,326 stock options with an exercise price of $0.4454, as part of a larger award, and executed a Power of Attorney for SEC compliance filings.

Summary

• Michael Byrnes, a Director of CERo Therapeutics Holdings, Inc. (CERO), was granted 9,326 stock options on May 30, 2025.
• These options have an exercise price of $0.4454 per share.
• This grant represents a 1/3 time-based portion of a larger award totaling 27,979 options.
• The 9,326 time-based options will vest in equal monthly installments from July 4, 2025, through March 4, 2026.
• The remaining portion of the 27,979 options is subject to specific performance conditions.
• All granted options are set to expire on May 29, 2035.
• A Limited Power of Attorney was executed by Michael Byrnes on June 2, 2025, designating Andrew Albert Kucharchuk and Chris Ehrlich as attorneys-in-fact for the purpose of executing and filing various U.S. Securities and Exchange Commission (SEC) forms, including Forms ID, 3, 4, 5, and Schedules 13D/G.

Sentiment

Score: 7

Explanation: The document details a routine compensation grant to a director, which is generally viewed as a positive for aligning management interests with shareholders, without indicating any negative operational or financial news.

Positives

• The grant of stock options to Director Michael Byrnes aligns his financial interests with those of the company's shareholders, incentivizing long-term value creation.
• The options have a long expiration date of May 29, 2035, providing a sustained long-term incentive for the director.

Negatives

• The exercise of these stock options in the future could lead to a degree of share dilution for existing shareholders.

Risks

• A significant portion of the total option award (2/3 of 27,979 options) is subject to performance conditions, meaning the full award may not be realized if these conditions are not met.

Future Outlook

The future outlook includes the vesting of the time-based stock options in equal monthly installments through March 2026 and the potential vesting of additional performance-based options contingent on meeting specified conditions.

Management Comments

• "The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigneds responsibilities to comply with Section 16 or Regulation 13D-G of the Securities Exchange Act of 1934, as amended."
• "The undersigned hereby agrees to indemnify the attorneys-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to the attorneys-in-fact."

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages designed to align leadership incentives with long-term shareholder value.

Comparison to Industry Standards

• The use of stock options as a compensation mechanism for directors is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule, combining time-based and performance-based components, is a common approach to balance retention incentives with performance alignment, consistent with compensation structures seen in comparable companies.

Corporate Governance

Related Party Transactions

• The grant of stock options to Michael Byrnes, a director of CERo Therapeutics Holdings, Inc., constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also improved alignment of the director's incentives with long-term shareholder value creation.
• Management/Directors: Michael Byrnes receives equity-based compensation, incentivizing his continued commitment and performance for the company.

Next Steps

• Continued monthly vesting of the time-based stock options through March 2026.
• Evaluation of performance conditions for the remaining portion of the stock option award.

Key Dates

Recommendation

Keywords

CERo Therapeutics, CERO, Stock Option Grant, Director Compensation, SEC Filing, Form 4, Beneficial Ownership, Power of Attorney, Executive Compensation, Equity Incentive